These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
based drug design represents a promising drug discovery paradigm complimentary
to the traditional HTS based lead generation strategy. How to link fragment
structures to increase compound affinity is remaining a challenge task in this
paradigm. Hereby a novel deep generative model (SyntaLinker) for linking fragments
is developed with the potential for applying in the fragment-based lead
generation scenario. The state-of-the-art transformer architecture was employed
to learn the linker grammar and generate novel linker. Our results show that,
given starting fragments and user customized linker constraints, our SyntaLinker model can design abundant drug-like molecules fulfilling these constraints and
its performance was superior to other reference models. Moreover, several
examples were showcased that SyntaLinkercan be useful tools for carrying out
drug design tasks such as fragment linking, lead optimization and scaffold